Shots:
- Eli Lilly has reported topline P-III (monarchE) trial data assessing Verzenio (150mg, BID) + SoC adj. ET vs SoC adj. ET in 2 cohorts (N=5,637) for pts with HR+, HER2-, node-positive early breast cancer at high risk of recurrence
- Cohort 1 (n=5,120; FDA-approved) incl. pts with ≥4 positive nodes or 1–3 nodes plus tumor ≥5 cm or Grade 3, while Cohort 2 (n=517) incl. pts with 1–3 nodes & Ki-67 ≥20%, who failed to meet Cohort 1 criteria
- Trial showed significant improvement in OS at 2yrs., while 7yr. analysis showed sustained benefit in IDFS & DRFS; Results will be published in a journal, shared at a medical meeting & with global health regulatory bodies
Ref: Eli Lilly | Image: Eli Lilly| Press Release
Related News:- Eli Lilly Collaborates with Superluminal Medicines to Develop Small Molecule for Cardiometabolic Diseases and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
